Applying New Science to Improve Outcomes for Patients with Multiple Sclerosis

This CME program will feature content presented at the the 69th Annual American Academy of Neurology (AAN) Meeting held in Boston, Massachusetts. Three expert faculty will analyze recent therapeutic advances in the treatment and management of patients with multiple sclerosis. The clinical relevance of emerging and emerged trial data will be reviewed. Faculty will discuss strategies for utilizing the multidisciplinary team approach to develop and implement personalized treatment plans, accommodating patient-specific disease characteristics. Upon completion of the activity, learners will have a better grasp of evolving science in the field of multiple sclerosis as it relates to clinical practice. 

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with multiple sclerosis.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to:

  1. Review the recent advances in immune science for multiple sclerosis.
  2. Examine emerging clinical trial data for the treatment of multiple sclerosis as present at AAN 2017.
  3. Develop data-driven treatment plans to effectively address patient-specific characteristics and improve outcomes for patients with multiple sclerosis. 

FACULTY

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

Joseph R. Berger, MD
Professor of Neurology and MS Division Co-Chief
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Suhayl Dhib-Jalbut, MD
Chairman, Department of Neurology
Professor of Neurology
Rutgers University
New Brunswick, New Jersey

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:

Fred D. Lublin, MD

Consultant/Advisor: AbbVie Inc.; Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Akros Pharma Inc.; Amgen Inc.; Atara Biotherapeutics; Bayer AG; Biogen; Celgene Corporation; Coherus Bioscience; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Mapi-Pharma Ltd.; MedDay; MedImmune; Novartis Pharmaceuticals Corporation; Polypharma; TG Therapeutics, Inc.; Toyama Chemical Co. Ltd.; Receptos Services LLC; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.

Grant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.; Transparency Life Sciences

 Speaker's Bureau: Genentech, Inc.; Genzyme Corporation

Joseph R. Berger, MD

Consultant/Advisor: Amgen Inc.; AstraZeneca; Bayer AG; Biogen; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd ; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Incyte Corporation; Inhibikase Therapeutics, Inc.; Janssen Global Services, LLC; Johnson & Johnson Services, Inc; Novartis Pharmaceuticals Corporation; PAREXEL International Corporation; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.

Grant/Research Support: Biogen; Teva Pharmaceutical Industries Ltd.

Suhayl Dhib-Jalbut, MD

Consultant/Advisor: Genzyme Corporation; Mallinckrodt; Teva Pharmaceutical Industries Ltd.

Grant/Research Support: Biogen; Teva Pharmaceutical Industries Ltd

Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Sandy Breslow; Alison Kemp; Leah Johnson and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months. 

Financial Support

This CME activity has been supported by an independent educational grant from Biogen.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
05/26/2017
Course expires: 
05/25/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
05/26/2017
Course expires: 
05/25/2018
Please login or register to take this course.